1Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Estern Cooperative Oncology Group study. Blood, 2000, 96: 4075-4083.
2Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol, 1993, 11:116-124.
3Higashi Y, Turzanski J, Pallis M, et al. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colonystimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. Br J Haematol, 2000, 111: 565-569.
4Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol, 2003, 82: 231-235.
5Advani RA, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood,1999, 93: 787-795.
6Wrzesien-Kus A, Robak T, Lech-Maranda E, et al. A multicenter,open, non-comparative, phase Ⅱ study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia--a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol, 2003, 71: 155-162.
9Jackson G, Taylor P, Smith GM, et al. A multicentre, open, noncomparative phase Ⅱ study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess blasts in transformation. Br J Haematol,2001 ; 112 : 127 - 137
10Higashi Y, Turzanski J, Pallis M, et al. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic lenkaemia. Br J Haematol, 2000 ; 111:565 - 569
